Koro Pharmaceuticals and Inofab Health have decided to cooperate in the sales and marketing of Inofab’s digital respiratory health products in Turkey.
The COVID-19 pandemic has caused interruptions in the normal diagnoses, treatment and follow-up activities in hospitals and clinics around the world, reducing patient access to non-pandemic related but necessary healthcare. The impact has been heavy on individuals living with chronic lung diseases such as Asthma, COPD and Cystic Fibrosis. It has also lead to an increase in demand for digital health and remote monitoring technologies that by-pass the limitations and challenges of in-clinic healthcare.
Inofab Health digital health solutions for chronic respiratory disease includes the world's first personal ultrasonic spirometer, designed and developed with indigenous capabilities in Turkey. Spirohome has reached users in 48 countries since its launch in June 2019. Testament to its user-oriented approach and design, Spirohome has received several international product design awards in the past year including the Good Design Awards 2019, Reddot 2020, Core77 Design Awards 2020.
Inofab Health respiratory care technologies have gained interest and traction during this COVID-19 pandemic period, as it became much more meaningful for patients to measure their lung function from the safety and convenience of their own homes. The closure of pulmonary function laboratories around the world as part of public health infection control measures meant that at-home solutions became a fundamental necessity for the ongoing care of most patients. Countries like Australia, Germany, UK, and Spain are leading the way in terms of demand for Inofab Health's Spirohome Personal spirometer and Spirocloud remote monitoring platform.
To bring these solutions to health professionals and end-users in Turkey, Inofab Health’s marketing and sales activities in the field of diagnostics and life sciences will be conducted with Koro. With over 30 years of experience, Koro will undoubtedly ensure that the benefits of digital health and remote monitoring reach respiratory health professionals and patients nation-wide.
About Koro Pharmaceuticals
They started their journey in 1988 under the name of Labotest. Since 2005, they continue as Koro İlaç ve Sağlık Ürünleri San. ve Tic. A.S. (www.koroilac.com) which is a biotechnology company that always prioritizes quality, is open to technological developments and operates in the field of diagnostics and life sciences with its expert staff.